Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice...
Oxford BioDynamics PLC 21 June 2024 Oxford BioDynamics Plc ("OBD...
Oxford BioDynamics PLC on Tuesday reported strong revenue growth on the back of the increased commercialisation of it ...
Oxford BioDynamics PLC 18 June 2024 Oxford BioDynamics Plc ("OBD" or the "Company" and, together with its subsidiaries, the "Group") ...
Oxford BioDynamics PLC 06 June 2024 Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") ...
EpiSwitch® Specific Canine Blood (EpiSwitch® SCB) test is a new canine multi-cancer diagnostic test based on OBD’s non-invasive EpiSwitch® array...
Oxford BioDynamics PLC on Tuesday announced the development of a canine cancer diagnostic test based on its EpiSwitch ...
Oxford BioDynamics PLC 04 June 2024 Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") OBD Oxford...
Oxford BioDynamics PLC 24 May 2024 Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Notice of...
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by ...
Oxford BioDynamics PLC 23 May 2024 Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Oxford...
Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic. The partnership will see the ...
Oxford BioDynamics PLC 21 May 2024 Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Oxford...
Oxford BioDynamics PLC 16 May 2024 Oxford BioDynamics and King's College London collaborate to develop EpiSwitch® prognostic and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.